Efficacy and Tolerability of Two Different Kinds of Titration of Paroxetine Hydrocloride Solution: an Observational Study
- PMID: 29713104
- PMCID: PMC5875366
- DOI: 10.64719/pb.4567
Efficacy and Tolerability of Two Different Kinds of Titration of Paroxetine Hydrocloride Solution: an Observational Study
Abstract
Background: Depressive disorders are expected to be the second highest cause of morbidity in the world until few years. Moreover, patients with depression frequently show many side effects and low compliance to therapy. To find a more tolerated and more efficacy therapy is a growing need.
Objective: This observational study investigates the efficacy, safety and tolerability of paroxetine hydrochloride comparing slow versus standard titration in a population affected by Depressive Disoders (according to DSM 5).
Methods: 186 outpatients were assessed throught the following scales: Hamilton Depression Rating Scale (HDRS) for depression and World Health Organization Quality of Life Scale Bref for the perceived quality of life (WHOQOL BREF). Treatment-emerged Adverse Events (TEAEs) were recorded throught self-reports. Statystical analysys was performed by GraphPad Prism Version 5.1.
Results: The efficacy of paroxetine was confirmed in both titrations by the number of clinical remitters (HDRS ≤ 7 at 12 weeks for 53% of the standard titration group and 58% of the slow titration group), without differences. About safety and tolerability there were more frequent TEAEs among the standard titration group (p < 0.01). Comparing WHOQOL BREF between the two groups at the recruitment and at the twelth week emerged a statistically significant difference (p = 0.003), with highest scores reached in slow titration group.
Conclusions: Although the short observation period is an evident limit, this study is consistent to the literature about the efficacy of both titrations of paroxetine to improve depression and shows promising results about the increased tolerability of paroxetine slow titration.
Keywords: adverse effects; antidepressants; drug tolerance; paroxetine hydrochloride; serotonin reuptake inhibitors.
Figures
References
-
- Stahl SM, Fava M, Trivedi MH et al. Agomelatine in the tratment of Majore Depressive Disorder: an 8 week, multicenter, randomized, Placebo-Controlled Trial. J Clin Psichiatry. 2010;71:5. - PubMed
-
- Olesen J, Gustavsson A, Svensson M et al. The economic cost of brain disorders in Europe. European Journal of Neurology. Eur J Neurol. 2012;19:155–162. - PubMed
-
- Poloni N, Callegari C, Buzzi A et al. The Italian version of ISOS and RSQ, two suitable scales for investigating recovery style from psychosis. 2010;19:352–359. - PubMed
-
- APA. The American Journal of Psychiatry. Third. American Psychiatric Publishing, Inc; 2010. Practice Guideline for the Treatment of Patients with Major Depressive Disorder.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
